comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 16:49:16 - browse：57

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Devoted Health’s losses in Medicare Advantage persist

focus

WSS

Eyeing GLP

Problems with a popular proposal to regulate AI in health care

H5N1 virus can be tracked in retail milk, scientists say

ASCO eve: Let’s set the table for this year's meeting

H5N1 bird flu outbreak: Second human case reported, in Michigan

Problems with a popular proposal to regulate AI in health care

hotspot

comprehensive

The need-to-know this morning

Novavax’s money is going in the wrong direction

explore

Hepatitis C has a cure — but many Americans still lack access to it

Eyeing GLP

Medicare proposal to cover medical devices draws a mixed reaction

ASCO eve: Let’s set the table for this year's meeting

Guidelines to prevent youth baseball injuries need more muscle

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD: Venture capital, Gilead, and more M&A

Bright Health sells Medicare Advantage business to Molina

Padmanee Sharma of MD Anderson at center of lawsuit over credit

knowledge

A protest over insulin prices is seen as a fight for life

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Bernie brings in new pharma CEOs to talk drug prices

AI gets buy

What’s missing from the debate over nursing home staff minimums

Padmanee Sharma of MD Anderson at center of lawsuit over credit

leisure time

focus

leisure time

focus